The second one! It's clear that "Kaglie Net Film" has been approved for sale.

On September 28th, Zhengda Tianqing Class 4 generic drug Kaglie Net Tablet was approved for listing by NMPA, becoming the second domestic generic drug market after Haussen Pharmaceuticals.
Kagligne is a SGLT-2 inhibitor developed by Johnson and Johnson to reduce glucose levels in the blood by inhibiting the re-absorption of glucose by the nephroidal tube, thus achieving the role of treating people with type 2 diabetes, and the drug is combined to treat patients with type 2 diabetes at all stages because they do not rely on insulin secretion and action levels.
2019, Johnson and Johnson Caglie's net sales were $735 million.
on December 24, 2019, the first copy of the HaussenKagli net film was launched. according to
Pharmaceutical Rubik's Cube PharmaGo database, of the four SGLT-2 inhibitors currently approved in China, in addition to the net approval of Haussen Pharmaceuticals Caglie, Engele Net has two generic drugs approved by Howson Pharmaceuticals and Colum Pharmaceuticals.
addition, Colum Pharmaceuticals filed a net listing application for Caglia in March.
several other SGLT-2 inhibitors, Aurobindo Pharma, Lu Anti-Pharmaceuticals and Fuyuan Pharmaceuticals have submitted applications for the listing of Dagle net generics, while Wanbang Bioscics, Zhengda Tianqing, Osaikang and Aurobindo Pharma have submitted applications for the listing of Ngli net generics.
.